Does empagliflozin reduce left ventricular volumes in patients with HFrEF and type 2 diabetes or prediabetes?
Empagliflozin promotes favorable reverse LV remodeling in patients with HFrEF and dysglycemia, offering a potential mechanism for its known mortality and hospitalization benefits.
The sodium-glucose cotransporter 2 inhibitor empagliflozin reduced LV volumes in patients with HFrEF and type 2 diabetes or prediabetes. Favorable reverse LV remodeling may be a mechanism by which sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization and mortality in HFrEF. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03485092.
Lee et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: